Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Emma Bagshaw"'
Autor:
Kristl G Claeys, Renato Mantegazza, Hiroyuki Murai, Francesco Saccà, Sonia Berrih-Aknin, Nancy Law, Sarah Dewilde, Mathieu F Janssen, Emma Bagshaw, Hara Kousoulakou, Mark Larkin, Jon Beauchamp, Trevor Leighton, Sandra Paci
Publikováno v:
BMJ Open, Vol 11, Iss 7 (2021)
Introduction Myasthenia gravis (MG) is a rare, chronic, autoimmune disease, mediated by immunoglobulin G antibodies, which causes debilitating muscle weakness. As with most rare diseases, there is little patient-reported data with which to understand
Externí odkaz:
https://doaj.org/article/dbd0be896e044f488a9ab146511d3039
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Voriconazole is well established as standard treatment for invasive aspergillosis (IA). In 2017, isavuconazole, a new antifungal from the azole class, with a broader pathogen spectrum, was introduced in Sweden. A model has therefo
Externí odkaz:
https://doaj.org/article/20101d78b491468a8a5d7f835ec524c2
Publikováno v:
The Patient
Background and Objective Transfusion-dependent β-thalassemia (TDT) is a rare genetic disease characterized by a deficiency of functional β-globin, ultimately leading to lifelong dependence on blood transfusions. There is little patient- and caregiv
Autor:
Sonia Berrih-Aknin, Emma Bagshaw, Trevor Leighton, Renato Mantegazza, Hara Kousoulakou, Sandra Paci, Mark Larkin, Sarah Dewilde, Hiroyuki Murai, Nancy Law, Mathieu F. Janssen, Kristl G. Claeys, Jon Beauchamp, Francesco Saccà
Publikováno v:
BMJ Open
BMJ Open, BMJ Publishing Group, 2021, 11 (7), pp.e048198. ⟨10.1136/bmjopen-2020-048198⟩
BMJ Open, Vol 11, Iss 7 (2021)
BMJ Open, 11(7):e048198. BMJ Publishing Group
BMJ Open, BMJ Publishing Group, 2021, 11 (7), pp.e048198. ⟨10.1136/bmjopen-2020-048198⟩
BMJ Open, Vol 11, Iss 7 (2021)
BMJ Open, 11(7):e048198. BMJ Publishing Group
International audience; Download PDFPDFNeurologyProtocolPatient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG) Sonia Berrih-Aknin1, Kristl G Claeys2,3, Nancy Law4, Renato Mantegazza5
Publikováno v:
Future Microbiology
Aim: Invasive mold diseases (IMDs) are associated with significant morbidity and mortality. Approved treatments include voriconazole (VORI), liposomal amphotericin B (L-AMB), posaconazole (POSA) and isavuconazole (ISAV). A UK-based economic model was
Autor:
Anna L. David, Adalina Sacco, Jan Deprest, Catherine Ferguson, Lennart Van der Veeken, Tim Van Mieghem, Emma Bagshaw
Publikováno v:
Obstetrical & Gynecological Survey. 74:451-453
OBJECTIVE To establish maternal complication rates for fetoscopic or open fetal surgery. METHODS We conducted a systematic literature review for studies of fetoscopic or open fetal surgery performed since 1990, recording maternal complications during
Autor:
Oliver A. Cornely, Michael Blackney, J Posthumus, D. Kuessner, Emma Bagshaw, Cesar Escrig, Sebastian M. Heimann
Publikováno v:
Future Microbiology. 12:515-525
Aim: Mucormycosis is a fungal infection associated with high mortality. Until recently, the only licensed treatments were amphotericin B (AMB) formulations. Isavuconazole (ISAV) is a new mucormycosis treatment. A UK-based economic model explored trea
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-11 (2019)
BMC Infectious Diseases
BMC Infectious Diseases
Background Voriconazole is well established as standard treatment for invasive aspergillosis (IA). In 2017, isavuconazole, a new antifungal from the azole class, with a broader pathogen spectrum, was introduced in Sweden. A model has therefore been d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e6160d08bdd346a0af6ffdb1fe00f93
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-378380
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-378380
Publikováno v:
Journal of medical economics. 19(12)
Overactive bladder (OAB) is a common condition that has a significant impact on patients' health-related quality-of-life and is associated with a substantial economic burden to healthcare systems. OnabotulinumtoxinA has a well-established efficacy an
Autor:
J Posthumus, D. Kuessner, Emma Bagshaw, Oliver A. Cornely, Sebastian M. Heimann, Michael Blackney
Publikováno v:
Value in Health. 19:A417